๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University201 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School89 Nanjing First Hospital, Nanjing Medical University68 The Second Hospital of Nanjing Medical University32 Nanjing Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanjing

1193 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Active, closed
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
NCT06174402Primary Biliary Cholangitis
Han Ying
Phase 2/3
184
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Yanโ€™an, Kunming, Beijing
2023-08-21
Recruiting
RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
NCT06058078Lupus Nephritis
Jiangsu Renocell Biotech Company
Phase 2
60
Nanjing
2023-08-17
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
NCT06577792Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Active, closed
Clinical Study of TCR-like CAR-T Cell Targeted MSLN in the Treatment of Ovarian Cancer
NCT05963100Safety and Efficacy of TCR-like CAR-T
Zhongda Hospital
Phase 1/2
10
Nanjing
2023-08-07
Recruiting
Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position
NCT06572501Renal Tumor, Prone Position, Robotic Assisted Partial Nephrectomy
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2023-08-06
Recruiting
High Resolution Diffusion Weighted Imaging in Prostate
NCT06636747Prostate Cancer, Prostate Disease
The First Affiliated Hospital with Nanjing Medical University
Observational
500
Nanjing
2023-08-01
Recruiting
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
NCT05983783Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect
The First Affiliated Hospital with Nanjing Medical University
Phase 3
200
Nanjing
2023-08-01
Recruiting
Washed Microbiota Transplantation for Chronic Constipation in Adults
NCT06106685Constipation
The Second Hospital of Nanjing Medical University
Phase 1/2
18
Nanjing
2023-07-24
Recruiting
Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion
NCT05903560Acute Ischemic Stroke
Jinling Hospital, China
Not applicable
386
Nanjing
2023-07-22
Recruiting
Washed Microbiota Transplantation for Clostridioides Difficile Infection
NCT06106698Clostridioides Difficile Infection
The Second Hospital of Nanjing Medical University
Observational
100
Nanjing
2023-07-22
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Nanchang
2023-07-11
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Taiho Oncology, Inc.
Phase 2
120
Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou
2023-07-05
Recruiting
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
NCT06287541Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
428
Nanjing
2023-07-01
By invitation
Identifying Vulnerable CoronAry PLaqUes With Artificial IntElligence-assisted CT Angiography
NCT06025305Coronary Artery Disease, Plaque, Atherosclerotic
Jinling Hospital, China
Observational
2,000
Nanjing
2023-07-01
Recruiting
Safety and Efficacy of NK510 to Treat NSCLC
NCT06097962NSCLC
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
12
Nanjing
2023-07-01
Recruiting
Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population
NCT05725096Statin, Cardiovascular Risk Factors, Primary Prevention, Adherence, Medication
Zhang longjiang,MD
Not applicable
3,400
Nanjing
2023-06-28
Active, closed
Clinical Efficacy of Early Left Bundle Branch Pacing for Cardiac Resynchronization Therapy
NCT06126081Heart Failure, Left Bundle Branch Pacing
Fu Wai Hospital, Beijing, China
Not applicable
36
Beijing, Nanjing
2023-06-26
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Recruiting
Omission of SLNB in CN0 Early Breast Cancer
NCT05935150Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes, Sentinel Lymph Node
The First Affiliated Hospital with Nanjing Medical University
Not applicable
311
Nanjing
2023-06-21
Recruiting
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
NCT05956639Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University
Phase 3
100
Nanjing
2023-06-20
Recruiting
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
NCT05830123Osteosarcoma, Sarcoma
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
NCT05931263Newly Diagnosed Peripheral T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3
104
Nanjing
2023-06-01
Recruiting
A Clinical Study of Inhaled Nitric Oxide in Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT05896800Chronic Obstructive Pulmonary Disease
The First Affiliated Hospital with Nanjing Medical University
Not applicable
24
Nanjing
2023-06-01
Recruiting
Dongzong Cardiovascular Bio-imaging Registry Study
NCT06894095Cardiovascular Diseases, Multi-omics, Living Environments, Pulmonary-cardiovascular Imaging
Jinling Hospital, China
Observational
50,000
Nanjing
2023-05-24
Recruiting
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
NCT05942625IgA Nephropathy, Focal Segmental Glomerulosclerosis
Hansoh BioMedical R&D Company
Phase 1
84
Nanjing
2023-05-23
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Recruiting
A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease
NCT07382258Chronic Obstructive Pulmonary Disease (COPD)
Novlead Inc.
Not applicable
16
Nanjing
2023-05-17
Recruiting
The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis
NCT05757505Intracranial Atherosclerosis
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
200
Luoyang, Wuhan, Nanjing, Nanchang, Changchun, Dalian, Baotou, Kunming
2023-05-11
Active, closed
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
NCT05658003Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Phase 2
63
Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou
2023-05-05
Active, closed
CRUSTAL Study in China
NCT05828186Coronary Artery Disease, Calcification
First Affiliated Hospital of Guangxi Medical University
Observational
200
Liuzhou, Yulin, Nanjing, Guilin, Guiping
2023-05-04
Recruiting
Application of CLCVP Technique in Early Intervention of CSA-AKI
NCT05855954Acute Kidney Injury
Nanjing First Hospital, Nanjing Medical University
Not applicable
200
Nanjing
2023-05-01
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2
199
Beijing, Nanjing, Tianjin
2023-04-21
Recruiting
Effect of Music Therapy in Mental Subhealth (EMTMS)
NCT05648539Depression, Anxiety
Jiangsu Province Nanjing Brain Hospital
Not applicable
150
Nanjing
2023-04-19
Recruiting
Immunotherapy with Autologous Tregs in T1DM
NCT06708780Type 1 Diabetes Mellitus
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1
20
Nanjing
2023-04-12
Recruiting
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission
NCT05909293Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2023-04-12
Recruiting
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
NCT05834764HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
188
Nanjing
2023-04-08
Recruiting
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05410925ST Elevation Myocardial Infarction
The First Affiliated Hospital with Nanjing Medical University
Phase 4
2,260
Nanjing, Changzhou, Chongqing, Dalian, Daqing, Dongguan, Fengcheng, Guangzhou
2023-04-08
Recruiting
IVUS-guided DES Implantation in Coronary Calcification
NCT05800002Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Not applicable
864
Nanjing
2023-04-07
Active, closed
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906Biochemically Recurrent Prostate Cancer
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Recruiting
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
NCT05967949PTCL
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2023-04-01
Not yet open
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
NCT05778097Prostate Cancer, Biochemical Recurrence, High Risk
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
103
Nanjing, Nantong
2023-04-01
Recruiting
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
NCT05683717B-Cell Malignancies
TransThera Sciences (Nanjing), Inc.
Phase 1
37
Nanjing
2023-03-30
Active, closed
PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI
NCT05457582Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention, Cardiovascular Events
Nanjing First Hospital, Nanjing Medical University
Not applicable
1,212
Nanjing
2023-03-30
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Recruiting
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
NCT05687357Gastric Cancer, Gastroesophageal-junction Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
140
Wuhan, Nanjing, Taiyuan
2023-03-15
Active, closed
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
NCT05735496Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
Recruiting
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT05753566Prostate Cancer, Biochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
96
Nanjing
2023-03
Recruiting
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
NCT05751967Primary Biliary Cholangitis
Xijing Hospital of Digestive Diseases
Phase 3
150
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Chengdu, Tianjin
2023-02-22
Recruiting
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
NCT05800977Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
Recruiting
Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
NCT05749822Primary Biliary Cholangitis
Xijing Hospital of Digestive Diseases
Phase 2/3
104
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an, Yanโ€™an
2023-02-17
Recruiting
The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
NCT06702683Gastric Carcinoma, Gastric Neoplasm, Gastric (cardia, Body) Cancer, Gastric Cancer Adenocarcinoma Metastatic
Lin Liu
Observational
112
Nanjing
2023-02-17
Recruiting
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
NCT05667506B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Phase 1/2
47
Hefei, Chongqing, Guangzhou, Wuhan, Nanjing, Xuzhou, Nanchang, Tianjin
2023-02-07
Recruiting
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
NCT05768464Non-clear Renal Cell Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
30
Nanjing, Nanning
2023-02-01
Recruiting
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
NCT05613478Hepatocellular Carcinoma, Immunotherapy, Preoperative
The First Affiliated Hospital with Nanjing Medical University
Phase 3
130
Nanjing
2023-01-31
Active, closed
The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection๏ผˆBROAD๏ผ‰
NCT05659641Aortic Dissection, Aneurysm, Dissecting, Aneurysm, Vascular Diseases
Permed Biomedical Engineering Co., Ltd
Not applicable
259
Hefei, Chongqing, Fuzhou, Shijiazhuang, Harbin, Wuhan, Nanjing, Nanchang
2023-01-18
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 3
606
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2023-01-10
Active, closed
Multimodal CT-Based Risk Stratification for Postoperative Local Recurrence in NSCLC: A Multicenter Study
NCT07552532Lung Cancer (NSCLC)
Guangming Lu
Observational
2,000
Nanjing
2023-01-01
By invitation
The Predictive Value of Molecular Diagnostic Techniques in the Antimicrobial- Resistance Phenotypes of Pathogens
NCT07035535Antimicrobial Drug Resistance, High-Throughput Nucleotide Sequencing
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2023-01-01
Recruiting
Daratumumab for Patients With Light Chain Amyloidosis
NCT06376214Light Chain (AL) Amyloidosis
Nanjing University School of Medicine
Not applicable
100
Nanjing
2023-01-01
Recruiting
A Prospective Study on the Treatment of cLM Based on ICG Imaging
NCT06275022Lymphatic Malformation
Nanjing Children's Hospital
Not applicable
110
Nanjing
2023-01-01
Active, closed
3D-CT-Based Prediction of Difficult Laryngoscopy in Infants With Pierre Robin Sequence
NCT07257276Pierre Robin Sequence (PRS), Difficult Laryngoscopy, Airway Management
Nanjing Children's Hospital
Observational
294
Nanjing
2023-01-01
Recruiting
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
NCT05917106Carcinoma, Renal Cell Carcinoma, RCC, Kidney Neoplasms
Jinling Hospital, China
Observational
450
Nanjing
2022-12-26
Recruiting
Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort
NCT05862103Acute Myocardial Infarction, Adverse Event
Yu Bo
Observational
15,000
Beijing, Guangzhou, Nanning, Shijiazhuang, Daqing, Zhengzhou, Nanjing, Nanchang
2022-12-21
Recruiting
Comparison of Two Stapled Antimesenteric Anastomosis for CD: a Randomized Control Trial Study
NCT05658081Crohn Disease, Recurrence
Jinling Hospital, China
Not applicable
236
Nanjing
2022-12-08
Recruiting
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
NCT05717790Nasopharyngeal Carcinoma by AJCC V8 Stage
Fourth Affiliated Hospital of Guangxi Medical University
Not applicable
288
Baise City, Guilin, Liuzhou, Nanjing, Qinzhou, Wuzhou
2022-12-01
Recruiting
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
NCT05709249Colon Cancer
Jiangsu Famous Medical Technology Co., Ltd.
Phase 3
730
Nanjing
2022-12-01
Not yet open
Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
NCT05613504Hot Flashes, Breast Cancer, Acupuncture
Nanjing University of Traditional Chinese Medicine
Not applicable
90
Nanjing
2022-12-01
Recruiting
Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
NCT05661786Chronic Hepatitis b
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
4,500
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2022-12
Active, closed
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104
NCT05476887Paroxysmal Nocturnal Hemoglobinuria
Kira Pharmacenticals (US), LLC.
Phase 2
35
Beijing, Nanjing, Tianjin, Zhengzhou
2022-11-25
Active, closed
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843Colitis Ulcerative
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Recruiting
A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma
NCT05917158Carcinoma, Upper Tract Urothelial Carcinoma, UTUC
Jinling Hospital, China
Phase 2
30
Nanjing
2022-11-23
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
Pfizer
Phase 3
1,116
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Active, closed
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227Eosinophilic Esophagitis
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Recruiting
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
NCT05817955MDS/MPN
The First Affiliated Hospital with Nanjing Medical University
Phase 2
50
Nanjing
2022-11-01
Active, closed
Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)
NCT05784142Lung Cancer, Non-small Cell
Jiangsu Cancer Institute & Hospital
Phase 2
55
Nanjing
2022-10-27
Recruiting
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
NCT05931328Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
28
Nanjing
2022-10-15
Active, closed
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
NCT05572957Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block
The First Affiliated Hospital with Nanjing Medical University
Not applicable
50
Beijing, Fuzhou, Nanjing, Dalian, Chengdu, Wenzhou
2022-10-14
Active, closed
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
NCT06166836Solid Tumor
InxMed (Shanghai) Co., Ltd.
Phase 1/2
140
Hangzhou, Bengbu, Changsha, Fuzhou, Ganzhou, Nanjing, Wuhan, Xuzhou
2022-10-12
Recruiting
Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
NCT05230017Anti Phospholipid Syndrome
Peking Union Medical College Hospital
Observational
2,000
Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang
2022-10-01
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 2
577
Chaoyang, Chengdu, Hangzhou, Jinhua, Nanjing, Wuhan
2022-09-19
Active, closed
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327Systemic Lupus Erythematosus
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Active, closed
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
NCT05459844Neuroendocrine Tumors
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
NCT05473624Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
Novartis Pharmaceuticals
Phase 3
506
Hefei, Chongqing, Nanjing, Nanchang, Pingxiang, Changchun, Taiyuan, Chengdu
2022-08-04
Recruiting
TreAtments and outComes in paTients With prImary CutAneous Lymphoma
NCT05518851Primary Cutaneous Lymphoma
Peking University First Hospital
Observational
3,000
Beijing, Guandong, Nanjing, Jinan
2022-08-01
Not yet open
Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
NCT05460819Hot Flashes, Breast Cancer, Acupuncture
Nanjing University of Traditional Chinese Medicine
Not applicable
90
Nanjing
2022-08-01
By invitation
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
NCT06048926Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Not applicable
30
Nanjing
2022-07-30
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
NCT05899049Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Recruiting
Long-Term Survival After LVAD Implantation in End-Stage Heart Failure
NCT07382284End-stage Heart Failure
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
300
Nanjing
2022-07-17
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Active, closed
INSPIRIS China PMCF Study
NCT05404880Aortic Valve Replacement
Edwards Lifesciences
Observational
255
Hefei, Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Xiโ€™an
2022-07-13
Recruiting
Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
NCT07064746Neuroblastoma (NB)
Nanjing First Hospital, Nanjing Medical University
Observational
150
Nanjing
2022-07-10
Active, closed
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446Coronary Artery Disease
Novartis Pharmaceuticals
Phase 3
609
Beijing, Nanjing, Shanghai
2022-07-08
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Recruiting
TAVR for Aortic Valve Disease
NCT05439863Aortic Valve Disease
Nanjing First Hospital, Nanjing Medical University
Observational
5,000
Nanjing
2022-07-01
Active, closed
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT05918133TNBC
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Rows per page Showing 901–1000 of 1193
Previous 8 9 10 11 12 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing?page=10

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,193 of those studies with a site in Nanjing.

How many clinical trials are recruiting in Nanjing?

713 of the 1,193 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 232 have not yet opened recruitment, 216 are active but closed to new participants, and 32 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.